BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,832,744 | -3.5% | 41,615 | +14.9% | 0.01% | 0.0% |
Q2 2023 | $2,934,065 | -51.7% | 36,223 | -56.2% | 0.01% | -53.8% |
Q1 2023 | $6,073,086 | -55.5% | 82,627 | -49.9% | 0.01% | -58.1% |
Q4 2022 | $13,643,867 | +31.8% | 164,781 | +352.0% | 0.03% | +24.0% |
Q3 2022 | $10,354,000 | -25.2% | 36,456 | -10.0% | 0.02% | -19.4% |
Q2 2022 | $13,843,000 | -25.4% | 40,522 | -5.4% | 0.03% | -11.4% |
Q1 2022 | $18,552,000 | -39.7% | 42,842 | -29.1% | 0.04% | -37.5% |
Q4 2021 | $30,764,000 | +39.5% | 60,465 | +32.8% | 0.06% | +36.6% |
Q3 2021 | $22,060,000 | +43.3% | 45,524 | +32.0% | 0.04% | +51.9% |
Q2 2021 | $15,398,000 | -10.0% | 34,482 | -23.0% | 0.03% | -3.6% |
Q1 2021 | $17,112,000 | -4.4% | 44,804 | -20.5% | 0.03% | -12.5% |
Q4 2020 | $17,891,000 | +27.8% | 56,352 | -0.3% | 0.03% | +33.3% |
Q3 2020 | $13,997,000 | -15.2% | 56,503 | -12.4% | 0.02% | -11.1% |
Q2 2020 | $16,497,000 | -10.9% | 64,520 | -33.9% | 0.03% | -12.9% |
Q1 2020 | $18,517,000 | +9.7% | 97,651 | +25.8% | 0.03% | +63.2% |
Q4 2019 | $16,872,000 | -30.4% | 77,608 | -37.3% | 0.02% | -34.5% |
Q3 2019 | $24,234,000 | -40.2% | 123,851 | -36.9% | 0.03% | -35.6% |
Q2 2019 | $40,552,000 | +1.0% | 196,142 | -3.1% | 0.04% | +4.7% |
Q1 2019 | $40,133,000 | -25.6% | 202,487 | -45.7% | 0.04% | -31.7% |
Q4 2018 | $53,955,000 | +16.8% | 372,820 | +64.7% | 0.06% | +43.2% |
Q3 2018 | $46,212,000 | +175.3% | 226,409 | +99.5% | 0.04% | +158.8% |
Q2 2018 | $16,787,000 | +103.5% | 113,463 | +107.8% | 0.02% | +88.9% |
Q1 2018 | $8,249,000 | +624.2% | 54,615 | +518.1% | 0.01% | +800.0% |
Q4 2017 | $1,139,000 | +48.7% | 8,836 | +39.4% | 0.00% | 0.0% |
Q3 2017 | $766,000 | -13.7% | 6,337 | -16.1% | 0.00% | 0.0% |
Q2 2017 | $888,000 | +13.3% | 7,556 | -2.0% | 0.00% | 0.0% |
Q1 2017 | $784,000 | +52.2% | 7,708 | +63.9% | 0.00% | 0.0% |
Q3 2016 | $515,000 | -16.9% | 4,702 | -25.4% | 0.00% | 0.0% |
Q2 2015 | $620,000 | -1.9% | 6,300 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $632,000 | -56.6% | 6,300 | -60.0% | 0.00% | -66.7% |
Q4 2014 | $1,455,000 | – | 15,743 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |